InMed Pharma Confirms Nasdaq Listing for Common Shares
Ticker: INM · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | 8-K |
| Filed Date | Jan 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, exchange-listing, compliance
TL;DR
**InMed Pharma's 8-K confirms its common shares are still listed on Nasdaq under INM.**
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on January 19, 2024, reporting an event that occurred on January 18, 2024. This filing is a routine disclosure indicating that the company's Common Shares, with no par value, are registered for trading on The Nasdaq Stock Market LLC under the symbol INM. This matters to investors because it confirms the company's continued listing and compliance with exchange requirements, which is fundamental for stock liquidity and investor confidence.
Why It Matters
This filing confirms InMed Pharmaceuticals' continued listing on Nasdaq, which is crucial for maintaining investor access and the stock's trading liquidity.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing confirming existing information and does not introduce new financial or operational risks.
Analyst Insight
A smart investor would view this as a routine compliance filing, confirming the company's continued listing on a major exchange, but it doesn't provide new information to warrant immediate action.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — the filer of the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where InMed's shares are registered
- INM (other) — the trading symbol for InMed Pharmaceuticals Inc.
FAQ
What is the purpose of this 8-K filing by InMed Pharmaceuticals Inc.?
The purpose of this 8-K filing is to report an event on January 18, 2024, specifically disclosing that InMed Pharmaceuticals Inc.'s Common Shares, with no par value, are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934 and traded on The Nasdaq Stock Market LLC under the symbol INM.
On what date was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 18, 2024.
What is the trading symbol for InMed Pharmaceuticals Inc. on The Nasdaq Stock Market LLC?
The trading symbol for InMed Pharmaceuticals Inc. on The Nasdaq Stock Market LLC is INM.
Where is InMed Pharmaceuticals Inc.'s principal executive office located?
InMed Pharmaceuticals Inc.'s principal executive office is located at Suite 310 - 815 W. Hastings Street, Vancouver, B.C. Canada, V6C 1B4.
Under which section of the Securities Exchange Act of 1934 are InMed Pharmaceuticals Inc.'s securities registered?
InMed Pharmaceuticals Inc.'s securities are registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-01-19 14:33:25
Filing Documents
- ea191889-8k_inmedpharma.htm (8-K) — 29KB
- ea191889ex99-1_inmedpharma.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-004799.txt ( ) — 222KB
- inm-20240118.xsd (EX-101.SCH) — 3KB
- inm-20240118_lab.xml (EX-101.LAB) — 33KB
- inm-20240118_pre.xml (EX-101.PRE) — 22KB
- ea191889-8k_inmedpharma_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 18, 2024, the Company will be participating in the Water Tower Research Fireside Chat Series on January 25, 2024, at 1:00 pm ET. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated January 18, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: January 19, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2